In detail, this study indicated that irAE development in any organ was significantly associated with better prognosis of patients with lung cancer, digestive and hepatobiliary-pancreatic cancer, renal and urothelial/bladder cancer, and skin cancer, and patients with PD-1 monotherapy, PD-L1 monotherapy, PD-1/PD-L1 and CTLA-4 combination therapy. Here, CTLA4 is linked to urinary bladder cancer.